Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?-Reference-Cited by-同舟云学术

Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?

Published:2014-05-07 Issue:6 Volume:127 Page:803-810
ISSN:0001-6322
Container-title:Acta Neuropathologica
language:en
Short-container-title:Acta Neuropathol

Author:

Watt Andrew D.,Crespi Gabriela A. N.,Down Russell A.,Ascher David B.,Gunn Adam,Perez Keyla A.,McLean Catriona A.,Villemagne Victor L.,Parker Michael W.,Barnham Kevin J.,Miles Luke A.

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00401-014-1290-2.pdf

Reference35 articles.

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356. doi: 10.1126/science.1072994

2. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for alzheimer’s disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700–1725

3. Miles LA, Crespi GAN, Doughty L, Parker MW (2013) Bapineuzumab captures the n-terminus of the alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci Rep 3. http://www.nature.com/srep/2013/130218/srep01302/abs/srep01302.html#supplementary-information

4. Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. Arch Neurol 69:1002–1010. doi: 10.1001/archneurol.2012.90

5. Rinne JO, Brooks DJ, Rossor MN et al (2010) 11c-pib pet assessment of change in fibrillar amyloid-β load in patients with alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372. doi: 10.1016/S1474-4422(10)70043-0

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease;Expert Opinion on Drug Discovery;2024-04-29

2. Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022;Journal of Alzheimer's Disease Reports;2024-01-29

3. Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History;Journal of Clinical Medicine;2024-01-17

4. Using Graph-Based Signatures to Guide Rational Antibody Engineering;Computer-Aided Antibody Design;2022-11-09

5. Molecular dynamics simulation analysis of the beta amyloid peptide with docked inhibitors;Bioinformation;2022-07-31